VAIA
UTHR icon

Virtus Alternative Investment Advisers’s United Therapeutics UTHR Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-55
Closed -$8K – 216
2020
Q4 		$8K Sell
55
-53
-49% -$6.96K 0.12% 90
2020
Q3 		$11K Buy
+108
New +$11.8K 0.2% 216

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Virtus Alternative Investment Advisers's UTHR Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of United Therapeutics (UTHR) in Q1 2021, closing a stake of 55 shares — an estimated $8K sold.

Virtus Alternative Investment Advisers first reported a position in UTHR in Q3 2020 and held it in 2 quarters. The position peaked at $11K in Q3 2020. 391 funds tracked by Wall St. Rank hold UTHR as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining United Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 55 United Therapeutics shares in Q1 2021, an estimated $8K.
  • Virtus Alternative Investment Advisers first reported a position in United Therapeutics in Q3 2020 and held it in 2 quarters.
  • Virtus Alternative Investment Advisers's United Therapeutics position peaked at $11K in Q3 2020.
  • 391 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.